Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced final results from a Phase 2 study, known as the 004 study, evaluating single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma. Results on prolonged infusion of carfilzomib and speed of response were also announced. These data were presented at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

Abstract #813: Final Results from the Bortezomib-Naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Results from the 004 Phase 2 study evaluated single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who had received one to three prior treatments and had not been previously treated with bortezomib. In 67 evaluable patients, carfilzomib achieved an overall response rate (ORR) of 52 percent and a clinical benefit rate (CBR) of 64 percent when administered at 27mg/m(2). Sixty-four percent of patients were refractory to their most recent therapy prior to entering the trial. Overall response is defined as a partial response or greater.[i]  The median time-to-progression (TTP), duration of response (DOR) and overall survival (OS) were not reached in this study, designed to provide patients with up to 12 cycles of carfilzomib.  Forty-two percent of patients completed greater than 10 cycles and 22 patients continued treatment beyond one year in the extension protocol PX-171-010.

"This Phase 2 study demonstrates promising single-agent activity of carfilzomib in patients with relapsed and/or refractory multiple myeloma who have not been previously treated with bortezomib," said Ravi Vij, M.D., Associate Professor, Department of Medicine,
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... a strategic collaboration focused on the development, manufacture ... pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s strength ... expertise in developing and manufacturing controlled substance APIs ... tech transfer processes into these facilities. The collaboration ...
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)...   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue ... media and a related cloud hosted biologistics ... shippers ("BioLife" or the "Company"), today announced ... company focused on developing and commercializing novel therapeutics ...
Breaking Medicine Technology:AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
... announces that a new market research report is ... Assist Devices - Global Pipeline Analysis, Opportunity Assessment ... http://www.reportlinker.com/p0330209/Cardiac-Assist-Devices---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2016.html Cardiac Assist Devices ... Forecasts to 2016 Summary ...
... The final hearing for approval of the class settlement ... by female sales representatives at Novartis Pharmaceutical Corporation is ... the courtroom of Judge Colleen McMahon of United States ... in Manhattan. The plaintiffs are seeking Court ...
Cached Medicine Technology:Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Cardiac Assist Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11Final Approval of Novartis Gender Discrimination Settlement Slated for November 19 2
(Date:8/31/2015)... ... August 31, 2015 , ... ... classes. , Starting September 1st they are offering pre and postnatal ... and "Healthy Body, Healthy Baby." , More information can be found at 248-601-6683. ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Coast ... Saturday, September 5, 2015, from 11 a.m. to 3 p.m. near Albertsons in the ... the opportunity to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article published ... Reconstructive Surgery Global Open Journal that discusses the future of 3-D printing technology as ... the future, customized implants, prosthetics, and other 3-D printed tools could be used to ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... Program at Monmouth, was one of the first doctors in the area to ... this new approach have been impressive: faster recovery, decreased immediate and long-term pain, ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... years as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical ... general orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , ...
Breaking Medicine News(10 mins):Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2
... Since antiquity, people have been fascinated with larger-than-life characters, ... Looking at the legions of fans mourning the loss ... a modern phenomenon. But from the gods on Olympus ... Sinatra in the 1950s to Brad and Angelina today, ...
... Continues as Growth of Company Exemplifies the Best in Retirement Living ... demand for senior housing will outpace supply in the coming years. Couple ... the future of the senior housing industry looks very different than it ... Aegis Living, a national leader in ...
... June 26 The Agency for Healthcare Research and Quality,s ... mixed reviews for the quality of care they provide. ... no state does well or poorly on all quality measures. ... Services is also releasing state-by-state reports on the health care ...
... deadlier than a heart attack, experts say, with chances for ... star Michael Jackson probably did not die on Thursday of ... sudden cardiac arrest, experts say. , It,s not yet clear ... Angeles home, but that assumption has been made by many ...
... , , Employers demonstrated commitment to making employee health ... 26 HealthFitness (NYSE Amex: FIT ) today ... as "2009 Best Employers for Healthy Lifestyles" by the National ... http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , , According to the ...
... therapy, researchers say , FRIDAY, June 26 (HealthDay News) ... are more likely to have a level of arterial ... blood pressure, a new study finds. , Arterial stiffness ... high blood pressure. , The study provides new insight ...
Cached Medicine News:Health News:The Psychology of Celebrity Worship 2Health News:The Psychology of Celebrity Worship 3Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 2Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 3Health News:New Snapshots Show States Vary Widely in Providing Quality Health Care 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 3Health News:Several HealthFitness Clients Earn National Recognition for Employee Health Initiatives 2
The unique RF-1501 optical design provides exceptional sensitivity in an incredibly compact instrument....
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
FlexStationII offers the highest level of flexibility in developing functional cellular assays and analyzing real time kinetic data....
... Modulus™ is a multifunctional ... to give you utmost ... luminescence, and absorbance. Modulus ... fluorometer, dedicated luminometer, or ...
Medicine Products: